Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36708579)

  • 1. Circulating MiRNA-373 as a Predictor of Response to Super-selective Transarterial Chemoembolization Bridging Therapy in Hepatocellular Carcinoma Patients Awaiting Liver Transplantation.
    Tork ASE; Kamel AAF; Zaki MA; Abo El-Wafa RAH; El-Assar OS; Ibrahim Abdelkarem OA
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):291-299. PubMed ID: 36708579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
    Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
    J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Changes in Circulating MicroRNA Levels in Liver Cancer Patients Undergoing Thermal Ablation and Transarterial Chemoembolization.
    Zavadil J; Juráček J; Čechová B; Andrašina T; Slabý O; Goldberg N
    Klin Onkol; 2019; 32(Supplementum1):164-166. PubMed ID: 31064190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization.
    Ali HEA; Emam AA; Zeeneldin AA; Srour R; Tabashy R; El-Desouky ED; Abd Elmageed ZY; Abdel-Wahab AA
    Clin Biochem; 2019 Mar; 65():45-52. PubMed ID: 30653948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation.
    Zhang W; Xu AH; Wang W; Wu YH; Sun QL; Shu C
    BMC Cancer; 2019 Nov; 19(1):1041. PubMed ID: 31690274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
    Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma.
    Carling U; Røsok B; Line PD; Dorenberg EJ
    Acta Radiol; 2019 Jun; 60(6):702-709. PubMed ID: 30205701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.
    Hyun D; Shin SW; Cho SK; Park KB; Park HS; Choo SW; Do YS; Choo IW; Shin JW; Lim SJ
    Acta Radiol; 2015 Dec; 56(12):1437-45. PubMed ID: 25480473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
    World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.
    Wei X; Zhao L; Ren R; Ji F; Xue S; Zhang J; Liu Z; Ma Z; Wang XW; Wong L; Liu N; Shi J; Guo X; Roessler S; Zheng X; Ji J
    Hepatology; 2021 Apr; 73(4):1381-1398. PubMed ID: 32609900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA H19 modulated by miR-146b-3p/miR-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma.
    Song Y; Xing H; Zhou L; Zhang N; Yang M
    Arch Toxicol; 2021 Sep; 95(9):3063-3070. PubMed ID: 34251499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival.
    Liu M; Liu J; Wang L; Wu H; Zhou C; Zhu H; Xu N; Xie Y
    PLoS One; 2014; 9(10):e109347. PubMed ID: 25275448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Kim SS; Cho HJ; Nam JS; Kim HJ; Kang DR; Won JH; Kim J; Kim JK; Lee JH; Kim BH; Lee MY; Cho SW; Cheong JY
    J Korean Med Sci; 2018 Jan; 33(1):e6. PubMed ID: 29215815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?
    Otto G; Schuchmann M; Hoppe-Lotichius M; Heise M; Weinmann A; Hansen T; Pitton MP
    J Hepatol; 2013 Aug; 59(2):279-84. PubMed ID: 23587474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size.
    Kim DJ; Clark PJ; Heimbach J; Rosen C; Sanchez W; Watt K; Charlton MR
    Am J Transplant; 2014 Jun; 14(6):1383-90. PubMed ID: 24801862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation.
    Terzi E; Ray Kim W; Sanchez W; Charlton MR; Schmeltzer P; Gores GJ; Andrews JC; Smyrk TC; Heimbach JK
    Liver Transpl; 2015 Feb; 21(2):248-57. PubMed ID: 25371111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
    Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
    Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.
    Park KH; Kim JH; Choe WH; Kwon SY; Yoo BC; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
    Korean J Gastroenterol; 2020 Mar; 75(3):147-156. PubMed ID: 32209803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.